Dear Editor,

Coronavirus disease 2019 (COVID-19) is associated with severe systemic inflammation and important elevation of fibrinogen and D-dimers that has been associated with a poor prognosis \[[@CR1], [@CR2]\]. This proinflammatory state might favor severe thromboembolic events and pulmonary embolism (PE).

We retrospectively reviewed characteristics of patients with confirmed SARS-CoV-2 infection and acute PE who were admitted to our tertiary ICU, which serves as an ECMO referral center for the Greater Paris. In accordance with the ethical standards of French legislation, only non-opposition of patient's surrogate for utilization of the deidentified data was obtained. The ICU database was registered with the national data protection authority (CNIL 1950673). No analysis for statistical significance was performed given the descriptive nature of the study.

From February 25, 2020, to April 6, 2020, 51 patients with confirmed SARS-CoV-2 infection were treated in our ICU, of whom 8 (16%) had confirmed severe PE. Patients' main characteristics are described in Table [1](#Tab1){ref-type="table"}. Four patients had PE while on VV-ECMO for severe ARDS. VA-ECMO was initiated in 3 other patients with refractory shock due to right ventricular failure, and one patient died of refractory cardiac arrest before ECMO could be installed. PE was suspected in 6 patients because of acute cor pulmonale at echocardiographic evaluation (online supplementary [data](#MOESM1){ref-type="media"}). PE diagnosis was confirmed by CT angiography (online supplementary [data](#MOESM1){ref-type="media"}) in 7 patients and by autopsy in one patient. All except one had received anticoagulation before PE diagnosis. Five patients had a very high level of fibrinogen, and all had important increase in D-dimers. As of April 6, 2020, 3 patients had died of multiple organ failure and 5 are still on MV and ECMO in the ICU. Table 1Characteristics of the 8 COVID-19 patients who developed massive pulmonary embolismPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Baseline characteristics Age6064415965615549 GenderMMMFMFFF BMI, kg/m^2^3227313932273330 Comorbidities  Hypertension01111101  Diabetes10000000  Active smoker00000000  Heart disease10001000  Stroke01000000Clinical characteristics at the time of PE diagnosis MV duration, days783100491 Reason for pulmonary embolism suspicion\*1, 2, 31, 31, 2142, 31, 2, 31 Norepinephrine, mg/h5030000.605 Acute kidney injury requiring dialysis01010000 On VV-ECMO for severe ARDS00110110 Anticoagulant therapyDalteparin, 5000 U/dayUFH, 12,000 U/dayEnoxaparin, 6000 U/dayUFH, 12,000 U/dayNoneEnoxaparin, 6000 U/dayEnoxaparin, 8000 U/dayEnoxaparin, 8000 U/dayLaboratory findings at the time of PE diagnosis D-dimers, ng/mL--728016,450\> 20,000--15,360\> 20,000\> 20,000 Fibrinogen, g/dl8.77.89.83.63.28.26.32.5 aPTT ratio\*\*1.051.181.271.14----1.231.2 Anti-Xa activity, U/mL--\< 0.2--\< 0.2----\< 0.2\< 0.2 Troponin, ng/L\< 132813159131642168 White blood cell count, G/L13.816.116.523.46.11117.512.8 Neutrophils, g/dl1314.414.220.63.49.915.310.9 Lymphocytes, g/dl0.40.50.71.71.70.71.31.3 Hemoglobin, g/dl1311.512.310.311.77.4710.5 Platelet count, × 10^3^/μL244610242128114237335228 pH7.066.947.417.457.277.297.27.06 pCO~2~, mmHg6359414043707936 pO2, mmHg40755466846060177 PO~2~/FiO~2~40755469NA6660177 Lactate, mmol/L28921.71.40.91.78.5 ASAT, U/L3743108715363622509 ALAT, U/L232945672442961207 LDH, U/L--5128218942643885415884 Total bilirubin, mmol/L86112162241825 Creatinine kinase, IU/L34103364810541234203151Outcomes Received VA-ECMO for PE-associated shock11000001 Current status as of April 6, 2020DeadDeadIn ICU, ongoing MV and ECMOIn ICU, ongoing MV and ECMODeadIn ICU, ongoing MV and ECMOIn ICU, ongoing MV and ECMOIn ICU, ongoing MV and ECMO*BMI* body mass index, *PE* pulmonary embolism, *MV* mechanical ventilation, *VA-ECMO* veno-arterial extracorporeal membrane oxygenation, *VV-ECMO* veno-venous extracorporeal membrane oxygenation, *aPTT* activated partial thromboplastin time\*Reason for pulmonary embolism suspicion: 1 = acute cor pulmonale on Doppler echocardiography, 2 = worsening hypoxemia, 3 = hypercapnia with preserved respiratory system compliance, and 4 = fortuitous discovery\*\*Ratio of the patient aPPT to the control aPPT used by the laboratory (control aPPT = 33 s for the La Pitié Salpêtrière laboratory)

We describe a series of 8 critically ill patients with massive PE following COVID-19 infection. Four of these patients developed PE while on VV-ECMO for severe ARDS, a condition that was not reported in the 156 patients included in the EOLIA trial \[[@CR3]\] who received ECMO and in the 350 VV-ECMO patients of the LIFEGARDS international multicenter prospective cohort \[[@CR4]\]. Interestingly, 7 of the 8 patients had received preventive anticoagulation that did not prevent PE. In 6 of the 8 patients, Doppler echocardiography showing acute right ventricle dilation prompted CT angiography that confirmed PE.

Massive PE in COVID-19 patients may be the consequence of sepsis-induced disseminated intravascular coagulation or to a specific procoagulant state caused by inflammation or virus-induced endothelial dysfunction \[[@CR5]\]. Important elevation of D-dimers was indeed reported in these patients and was associated with subsequent ARDS and in-hospital mortality \[[@CR5]\]. However, massive PE was not reported in previous series \[[@CR1], [@CR2]\], although it may have been the unproven cause of death in some patients.

Our observation has potential major clinical implications. First, higher level of anticoagulation might be considered in patients with the most severe forms of the disease, those with high D-dimers and, contrarily to our previous recommendation, in patients supported by VV-ECMO \[[@CR3]\]. Second, routine Doppler echocardiography should be performed daily to detect early signs of acute cor pulmonale in critically ill patients. Lastly, PE should also be suspected in COVID-19 patients with worsening hypoxemia or hypercapnia under mechanical ventilation.

This case series has several limitations. It is a small single-center case series of critically ill patients, we did not compare clinical and biological characteristics of patients with or without PE, and PE incidence could not be accurately estimated. However, we think that physicians should be warned about the occurrence of severe and potentially fatal PE in COVID-19 patients.
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